Making top-quality cancer care accessible to all.100% free, no account required.

Exploring the Benefits of Adding SBP-101 to Standard Pancreatic Cancer Treatment

NCT05254171 · Recruiting
About this trial

This trial looks at how well SBP-101 works when added to the standard treatment for pancreatic cancer. The standard treatment includes two medicines called nab-paclitaxel and gemcitabine. Doctors want to see if adding SBP-101 can improve overall health and quality of life for people with metastatic pancreatic ductal adenocarcinoma, which is a specific type of pancreatic cancer.

Locations and contact

This trial is running at 93 locations in 10 countries. 77 of them are currently recruiting.

United States14 locations · 9 recruiting
  • Columbia University Medical CenterNew York, New YorkRecruiting
  • Froedtert Hospital & the Medical College of WisconsinMilwaukee, WisconsinRecruiting
  • Henry Ford Health SystemDetroit, MichiganRecruiting
  • HOPE Cancer Center of East TexasTyler, TexasRecruiting
  • Medical Oncology Associates - SpokaneSpokane, WashingtonRecruiting
  • MultiCare Regional Cancer Center - TacomaTacoma, WashingtonRecruiting
  • Providence Medical FoundationFullerton, CaliforniaRecruiting
  • University of RochesterRochester, New YorkRecruiting
  • Yale Cancer CenterNew Haven, ConnecticutRecruiting
  • CentraCare HealthSaint Cloud, MinnesotaWithdrawn
  • Genesis Cancer and Blood Institute (SCRI)Hot Springs, ArkansasWithdrawn
  • Mark H Zangmeister Center - SCRI - PPDSColumbus, OhioTerminated
  • MedStar Georgetown University HospitalWashington D.C., District of ColumbiaActive Not Recruiting
  • Tennessee Oncology NASH - SCRI - PPDSNashville, TennesseeActive Not Recruiting
Spain24 locations · 23 recruiting
  • Clinica Universidad NavarraPamplona, NavarreRecruiting
  • Hospital de La Santa Creu i Sant PauBarcelona, MadridRecruiting
  • Hospital General Universitario Gregorio MarañonMadridRecruiting
  • Hospital Regional Universitario de Malaga - Hospital GeneralMálagaRecruiting
  • Hospital Universitario 12 de OctubreMadridRecruiting
  • Hospital Universitario CrucesBarakaldo, VizcayaRecruiting
  • Hospital Universitario de BadajozBadajozRecruiting
  • Hospital Universitario de JaenJaén, JaenRecruiting
  • Hospital Universitario de NavarraPamplona, NavarreRecruiting
  • Hospital Universitario Fundacion Jimenez DiazMadridRecruiting
  • Hospital Universitario Fundacion Jimenez DiazMadridRecruiting
  • Hospital Universitario Germans Trias i PujolBadalona, BarcelonaRecruiting
  • Hospital Universitario HM Sanchinarro - CIOCCMadrid, Madrid, Communidad DelawareRecruiting
  • Hospital Universitario La Paz - PPDSMadridRecruiting
  • Hospital Universitario Marques de ValdecillaSantander, CantabriaRecruiting
  • Hospital Universitario Ramon y CajalMadridRecruiting
  • Hospital Universitario Vall d'Hebron - PPDSBarcelonaRecruiting
  • Hospital Universitario Virgen de La ArrixacaEl Palmar, MurciaRecruiting
  • Hospital Universitario Virgen del Rocio - PPDSSevilleRecruiting
  • Hospital Universitario Virgen MacarenaSevilleRecruiting
  • ICO l'Hospitalet - Hospital Duran i ReynalsBarcelonaRecruiting
  • Institut Catala d'Oncologia GironaGironaRecruiting
  • MD Anderson Cancer Center Madrid - EspañaMadridRecruiting
  • Hospital Universitario A CoruñaA CoruñaActive Not Recruiting
Belgium11 locations · 10 recruiting
  • AZ GroeningeKortrijk, West-VlaanderenRecruiting
  • Centre Hospitalier de l'ArdenneLibramont, LuxembourgRecruiting
  • CHU de LiègeLiègeRecruiting
  • CHU UCL Namur asbl - Site GodinneYvoir, NamurRecruiting
  • Grand Hopital de Charleroi asblCharleroiRecruiting
  • Hôpital de JolimontLa Louvière, HainautRecruiting
  • Imelda VZWBonheiden, AntwerpenRecruiting
  • Onze-Lieve-VrouwziekenhuisAalst, Oost-VlaanderenRecruiting
  • UZ GentGhent, Oost-VlaanderenRecruiting
  • UZ LeuvenLeuvenRecruiting
  • Cliniques Universitaires Saint-LucBrussels, BelgiqueNot Yet Recruiting
Italy10 locations · 9 recruiting
  • Azienda Ospedaliera Universitaria Integrata Di VeronaVerona, VenitoRecruiting
  • Azienda Ospedaliero Universitaria PisanaPisa, TuscanyRecruiting
  • Azienda Unita Sanita Locale di Reggio Emilia IRCCSReggio Emilia, Emilia-RomagnaRecruiting
  • Fondazione IRCCS Policlinico San Matteo di Pavia-Vialle Camillo Golgi 19PaviaRecruiting
  • Instituto Europeo Di OncologiaMilan, LombardyRecruiting
  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l - PPDSMeldola, Emilia-RomagnaRecruiting
  • Ospedale Casa Sollievo Della Sofferenza IRCCSSan Giovanni Rotondo, ApuliaRecruiting
  • Ospedale San Raffaele S.r.l. - PPDSMilan, LombardyRecruiting
  • Ospedale Santa Maria Della Misericordia Di PerugiaTerni, UmbriaRecruiting
  • Ospedale degli InfermiCandiolo, PiedmontCompleted
Austria10 locations · 7 recruiting
  • A.ö. Krankenhaus der Barmherzigen BrüderWeinRecruiting
  • Kepler Universitätsklinikum LinzLinzRecruiting
  • Klinikum Klagenfurt Am WoertherseeKlagenfurt, CarinthiaRecruiting
  • Klinikum Wels-Grieskirchen GmbHWels, Upper AustriaRecruiting
  • Landesklinikum Wiener NeustadtWiener NeustadtRecruiting
  • Landeskrankenhaus FeldkirchRankweil, VorarlbergRecruiting
  • Universitätsklinikum St. PöltenSankt Pölten, Lower AustriaRecruiting
  • Ordensklinikum Linz, Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.HLinz, Upper AustriaNot Yet Recruiting
  • Pyhrn-Eisenwurzen Klinikum SteyrSteyr, Upper AustriaWithdrawn
  • Salzburg Cancer Research InstituteSalzburgActive Not Recruiting
South Korea6 locations · 6 recruiting
  • Asan Medical Center - PPDSSeoulRecruiting
  • CHA Bundang Medical Center, CHA UniversitySeoul, GyeonggidoRecruiting
  • Chonnam National University Hwasun HospitalHwasunRecruiting
  • National Cancer CenterSeoul, GyeonggidoRecruiting
  • Seoul National University HospitalSeoul, Seoul TeugbyeolsiRecruiting
  • Severance Hospital Yonsei University Health System - PPDSSeoul, Seoul TeugbyeolsiRecruiting
France5 locations · 5 recruiting
  • Centre François BaclesseCaen, CalvadosRecruiting
  • EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDSRennes, Ille-et-VilaineRecruiting
  • Hôpital de RangueilToulouse, Haute-GaronneRecruiting
  • Hopital Jean MinjozBesançon, DoubsRecruiting
  • Hopitaux de La TimoneMarseille, Bouches-du-RhôneRecruiting
Australia5 locations · 4 recruiting
  • Ashford Cancer Centre ResearchKurralta Park, South AustraliaRecruiting
  • Austin HospitalHeidelberg, VictoriaRecruiting
  • Canberra Region Cancer CentreGarran, Australia Capital TerritoryRecruiting
  • St John of God Murdoch HospitalMurdoch, Western AustraliaRecruiting
  • The Tweed HospitalTweed Heads, New South WalesWithdrawn
Germany5 locations · 2 recruiting
  • Charité - Universitätsmedizin BerlinBerlinRecruiting
  • Universitätsklinikum TübingenTübingenRecruiting
  • Universitätsklinikum Carl Gustav Carus an der TU DresdenDresden, SaxonyNot Yet Recruiting
  • Asklepios Klinik AltonaHamburgActive Not Recruiting
  • Klinikum WeidenWeidenActive Not Recruiting
United Kingdom3 locations · 2 recruiting
  • Derriford HospitalPlympton, DevonRecruiting
  • Hammersmith HospitalLondon, City of LondonRecruiting
  • Aberdeen Royal Infirmary - PPDSAberdeen, Aberdeen CityActive Not Recruiting
Who to ask about joining
Who can join

Adults aged 18 and older, both men and women, can join the trial if they have a confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma and have not received any treatment before. Other health conditions may affect eligibility, and the trial team will check if each person qualifies.

What happens during the trial

Participants will be randomly placed into one of two groups. One group will receive the standard treatment of nab-paclitaxel and gemcitabine along with SBP-101. The other group will receive the same standard treatment but with a placebo, which is a substance with no active medicine. Everyone will get care and monitoring during the trial.

The trial team

The trial is sponsored by Panbela Therapeutics, Inc. Dr. Michael J Walker is the study director leading the trial.

Important dates

The trial started on August 8, 2022, and is currently recruiting new participants. It is expected to finish by January 1, 2027.

Additional information

This trial is listed as NCT05254171. It is in Phase 2 and Phase 3, which means it is looking at how well the treatment works and checking its safety. The trial is FDA-regulated and aims to include about 600 participants.

Similar trials

Other recruiting trials for the same condition, with the eligibility rules written in plain language.

Browse similar trials
Talk to a specialist

Find a top oncologist who can tell you whether a trial is a sensible option for you.

Find a doctor
Cancer hospitals

The cancer centers running studies like this one, and what each is known for.

Browse hospitals